Novo-Backed Drugmaker Avalyn Soars 44% After $300 Million US IPO
Avalyn Pharma Inc. shares jumped 44% in its trading debut, after the biopharmaceutical company raised $300 million in an upsized US initial public offering.
By Avalon Pernell ยท Bloomberg
Avalyn Pharma Inc. shares jumped 44% in its trading debut, after the biopharmaceutical company raised $300 million in an upsized US initial public offering.